FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA

　　In September 2026,the U.S.Food and Drug Administration(FDA)officially approved Isembyld(apitegromab‑mstn)injection.As the world’s first therapeutic agent targeting skeletal muscle tissue for Spinal Muscular Atrophy(SMA),this approval marks a paradigm shift from solely protecting motor neurons to a dual"neuro-muscular"intervention strategy.The drug previously received Orphan Drug,Rare Pediatric Disease,and Fast Track designations.

　　Mechanism and Development

　　Developed by Scholar Rock,Isembyld is a fully human monoclonal antibody.Unlike existing SMN-enhancing therapies that protect motor neurons,Isembyld acts directly on skeletal muscle.It targets and inhibits the activation of myostatin,a protein that suppresses muscle growth.Administered via intravenous infusion once every four weeks,it is designed to complement SMN2-targeted treatments.

　　Indication and Patient Population

　　Isembyld is indicated for patients with SMA aged 2 years and older who are currently receiving standard-of-care SMN2-targeted therapy.​It is not approved for standalone use.The therapy addresses the unmet need in patients with Type 2 and Type 3 SMA who experience suboptimal muscle strength improvements despite ongoing neuronal protection.

　　Clinical Data and Safety

　　Approval was based on the Phase 3 SAPPHIRE trial(NCT05156320).In the study involving patients aged 2–21 who were unable to walk independently,34.2%of subjects in the 10 mg/kg Isembyld group achieved a≥3-point improvement in the HFMSE score at 52 weeks,compared to 13.5%in the placebo group.Safety data showed a manageable profile,with common adverse reactions including upper respiratory tract infections,vomiting,and cough.The labeling includes a warning for fracture risk,necessitating regular bone health monitoring.

　　Clinical Impact

　　Isembyld pioneers a"neuro-protection plus muscle enhancement"strategy.While it cannot reverse established muscle damage,early combination therapy offers the potential to stabilize motor function and slow disease progression,significantly advancing the standard of care for SMA.